Literature DB >> 9187111

p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.

C A Moskaluk1, R H Hruban, S E Kern.   

Abstract

Pancreatic adenocarcinoma is thought to arise from a noninvasive neoplastic precursor, the pancreatic intraductal lesion (PIL). Mutations of the K-ras gene are known to occur in PILs, but their high prevalence among PILs within the general population probably limit the use of K-ras as a marker of eventual clinical risk. In search of genetic constellations that might indicate the progression of some PILs toward an invasive phenotype, mutations at both the K-ras and p16 genes were sought within PILs of 10 pancreata resected for adenocarcinoma. K-ras mutations were present in most PILs and in nearly all PILs having nuclear atypia. In half of the patients, two or more unique K-ras mutations were identified among distinct PILs, which is evidence for the separate clonal evolution of multiple pancreatic neoplasms within individual patients. p16 alterations (one homozygous deletion and three point mutations) were found in 4 of the 10 carcinomas; these four pancreata harbored p16 alterations in three of nine PILs, of which one was a "histologically early" lesion. Two patients had p16 alterations in PILs matching those of the associated carcinomas. p16 mutations were not found in PILs of pancreata having wild-type p16 in the carcinoma, nor were they found in ducts having normal histology. It is suggested that alterations of the p16 gene affect a subset of PILs that contain mutations of the K-ras gene and that these mutations might identify high-risk precursors of the invasive malignancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187111

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  130 in total

Review 1.  [ZAP genes: characterizing the protein structure of a new family of proliferation associated genes in the exocrine pancreas].

Authors:  R Günther; H Zill; W E Schmidt; U R Fölsch
Journal:  Med Klin (Munich)       Date:  1999-04-15

Review 2.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

3.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

4.  Acinar-to-ductal metaplasia in pancreatic cancer development.

Authors:  Roland M Schmid
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 5.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

6.  Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.

Authors:  Karim M Eltawil; Paul D Renfrew; Michele Molinari
Journal:  HPB (Oxford)       Date:  2012-02-26       Impact factor: 3.647

7.  Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  M Porta; N Malats; L Guarner; A Carrato; J Rifà; A Salas; J M Corominas; M Andreu; F X Real
Journal:  J Epidemiol Community Health       Date:  1999-11       Impact factor: 3.710

8.  Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics.

Authors:  N Volkan Adsay
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

9.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 10.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.